EPS - Jazz Pharmaceuticals Non-GAAP EPS of $4.51 beats by $0.08 revenue of $957.32M beats by $15.16M
2023-08-09 16:09:03 ET
- Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q2 Non-GAAP EPS of $4.51 beats by $0.08 .
- Revenue of $957.32M (+2.6% Y/Y) beats by $15.16M .
- Raised full year 2023 financial guidance:
- Raised total and Neuroscience revenue guidance at the mid-points.
- Raised GAAP earnings per diluted share ( EPS ) to $6.60-$8.15.
- Raised non-GAAP adjusted EPS by $1.20 at the mid-point to $18.15-$19.00.
For further details see:
Jazz Pharmaceuticals Non-GAAP EPS of $4.51 beats by $0.08, revenue of $957.32M beats by $15.16M